Articles tagged "Kidney transplantation"

2020 American Transplant Congress
Improving DRG Based Reimbursement to Reflect Complexity of Kidney Transplant
I. R. Schwantes¹, M. Schnitzler², K. Lentine², A. Reed¹, D. A. Axelrod³
¹Surgery, University of Iowa, Iowa City, IA, ²Saint Louis University, St. Louis, MO, ³Surgery, Universtiy of Iowa, Iowa City, IA
*Purpose: More than 90,000 individuals await a kidney transplant (KTx) in the US, yet up to 20% of recovered kidneys are discarded. Organ Transplant Centers…
2020 American Transplant Congress
High Volume, Highly Efficient, Outcome- Centric KPD Program: A Single Center Experience with Direct Exchange Based Strategies
K. Al Meshari, D. Broering, I. Alahmadi, S. Raza, T. Ali, A. Alabbassi, H. Alahdal, F. Alzayer
King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
*Purpose: We report our three and a half year experience with direct exchange (loop) based strategy single center KPD program.*Methods: 1. Inclusion of HLA and…
2020 American Transplant Congress
Belatacept-Based, Calcineurin Inhibitor and Corticosteroid Free Immunosuppression: Differential Outcomes Based on Recipient Age
N. Wilson¹, A. R. Shields², D. Kaufman³, A. Wiseman⁴, A. L. Christianson¹, S. Tremblay¹, J. P. Leone⁵, A. J. Matas⁶, P. West-Thielke⁷, R. R. Alloway¹, E. S. Woodle¹
¹U Cincinnati, Cincinnati, OH, ²The Christ Hospital, Cincinnati, OH, ³U Wisconsin, Madison, WI, ⁴U Colorado, Denver, CO, ⁵Tampa General, Tampa, FL, ⁶U Minnesota, Minneapolis, MN, ⁷U Illinois Chicago, Chicago, IL
*Purpose: Age-based disparities have been described in calcineurin inhibitor (CNI)-based immunosuppression regimens, but are not well-described for belatacept (BELA)-based regimens. This study analyzed the effect…
2020 American Transplant Congress
Mortality Index Should Be Used to Provide Realistic Expectations Regarding Transplant Candidacy
Y. Chalicheemala¹, K. Chavin², T. Srinivas¹, A. Padiyar¹
¹Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, ²Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH
*Purpose: Renal transplant improves outcomes of well-selected elderly patients with end stage renal disease. Older patients with significant comorbidities may not live long enough to…
2020 American Transplant Congress
TRANSBIO Study: Clinical Evaluation of Immunobiogram, a Novel In Vitro Diagnostic Immunoassay to Guide Adjustment of Immunosuppressive Therapy in Kidney Transplantation
J. Pascual¹, C. Jiménez², M. Krajewska³, C. Kotton⁴, D. Seron⁵, J. Portolés⁶, O. Witzke⁷, S. S. Sorensen⁸, A. Andrés⁹, T. Díez¹⁰, A. Ortega¹⁰, I. Portero¹⁰
¹Consorci Mar Parc de Salut, Barcelona, Spain, ²La Paz Hospital, Madrid, Spain, ³Wroclaw Medical University, Wroclaw, Poland, ⁴Massachusetts General Hospital, Boston, MA, ⁵Vall d’Hebron Hospital, Barcelona, Spain, ⁶Puerta de Hierro Mahadahonda Hospital, Madrid, Spain, ⁷University Hospital Essen, University Duisburg-Essen, Essen, Germany, ⁸Rigshospitalet, Copenhagen, Denmark, ⁹12 de Octubre Hospital, Madrid, Spain, ¹⁰Biohope Scientific Solutions for Human Health SL, Madrid, Spain
*Purpose: Immunobiogram (IMBG) is a first-in-class blood-based pharmacodynamic immunoassay that provides the sensitivity/resistance profile of each patient’s lymphocytes to a panel of immunosuppressive drugs (IS).…
2020 American Transplant Congress
Clinical Significance of T Cell and B Cell Epitope Prediction as a Risk Factor of De Novo DSA Production after Kidney Transplantation
T. Kobayashi¹, K. Iwasaki¹, T. Tomosugi², Y. Miwa¹, M. Niemann³, E. Spierings⁴, K. Horimi¹, Y. Matsuoka¹, A. Takeda², N. Goto², S. Narumi², Y. Watarai²
¹Aichi Medical University School of Medicine, Nagakute, Japan, ²Nagoya Daini Red Cross Hospital, Nagoya, Japan, ³PIRCHE AG, Berlin, Germany, ⁴UMC Utrecht, Utrecht, Netherlands
*Purpose: Chronic antibody-mediated rejection caused by de novo DSA (dnDSA) is a major cause of graft failure. Risk prediction of dnDSA would be important for…
2020 American Transplant Congress
Longer-Term Outcomes from the THINKER and EXPANDER Trials of Transplantation Using HCV-Viremic Kidneys
V. S. Potluri¹, F. Naqvi², P. Reese¹, M. Shah¹, D. Brown², S. Prenner¹, A. Loupy³, A. Woodards¹, P. Abt¹, E. Blumberg¹, J. Trofe-Clark¹, D. Segev², R. Bloom¹, D. Sawinski¹, C. Durand², P. Porrett¹, M. Levine¹, D. Goldberg⁴, N. Desai²
¹University of Pennsylvania, Philadelphia, PA, ²Johns Hopkins, Baltimore, MD, ³Paris Transplant Group, Paris, France, ⁴University of Miami, Miami, FL
*Purpose: The practice of transplanting HCV-viremic kidneys into HCV-negative recipients has become more common, but longer-term outcomes have not been reported. We present data on…
2020 American Transplant Congress
Outcomes Associated with Mycophenolate Weight-Based Dosing in Varying Immunologic Risk Kidney Transplant Recipients
A. A. Al-Bahou, A. R. Webb, M. Bloxam, L. J. Bowman Anger, R. S. Baliga, A. J. Brueckner
Tampa General Hospital, Tampa, FL
*Purpose: Mycophenolate acid (MPA) is traditionally dosed in kidney transplant recipients (KTR) using the FDA-approved fixed dosing which is irrespective of patient-specific variables such as…
2020 American Transplant Congress
Recurrent Lupus Post Kidney Transplantation- The Histological and Clinical Characteristics
A. Bentall¹, W. Jiqiu², A. Kattah¹, M. L. Gonzalez Suarez³, F. G. Cosio¹, M. Mai⁴, H. Khamash⁵, M. D. Stegall⁶, H. Amer¹, L. D. Cornell⁷, F. Fervenza¹, M. P. Alexander⁷
¹Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, ²National Clinical Research Center of Kidney Diseases, Nanjing University, Nanjing, China, ³Department of Nephrology, University of Mississippi Medical Center, Jackson, MS, ⁴Division of Nephrology and Hypertension, Mayo Clinic, Jackonville, FL, ⁵Division of Nephrology and Hypertension, Mayo Clinic, Scottdale, AZ, ⁶Department of Transplant Surgery, Mayo Clinic, Rochester, MN, ⁷Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
*Purpose: Lupus nephritis (LN) progresses to ESRD in
2020 American Transplant Congress
Early Experience Transplanting Undocumented Immigrants with ESRD at a Single Institution: Outcomes and Challenges
R. T. Christie¹, R. M. Nygaard², C. J. Richardson¹, M. J. Hill¹, T. Anderson-Haag³, A. Israni⁴, P. A. Stahler¹
¹Transplant Surgery, Hennepin Healthcare, Minneapolis, MN, ²Surgery, Hennepin Healthcare, Minneapolis, MN, ³Transplant Pharmacy, Hennepin Healthcare, Minneapolis, MN, ⁴Nephrology, Hennepin Healthcare, Minneapolis, MN
*Purpose: In July of 2016, Minnesota became the second state in the nation to provide coverage for kidney transplantation to patients, regardless of immigration status,…